Work

Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC)

Year: 2005

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2005.23.16_suppl.563

Authors: K. D. Miller, H. J. Burstein, A. D. Elias, H. S. Rugo, M. A. Cobleigh, M. D. Pegram, P. D. Eisenberg, M. Collier, B. J. Adams, C. M. Baum

Institutions: University of California, Los Angeles, University of California, San Francisco, Pfizer (United States), Dana-Farber Cancer Institute, Indiana University Indianapolis

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2278944712

Cites:

Cited by: 74

Related to: 10